claim
The utility of PET radioligands such as [18F]setoperone, [18F]altanserine, and [11C]MDL100907 is limited by methodological issues inherent in evaluating agonist compounds using antagonist PET radioligands.

Authors

Sources

Referenced by nodes (1)